

NOTICE OF DISCONTINUANCE OF A CLASS ACTION

1. On March 24, 2014, the Plaintiff instituted a Motion to Authorize the Bringing of a Class Action and to Ascribe the Status of Representative (the “Motion for Authorization”) in the Superior Court of Quebec, district of Montreal, under file number 500-06-000688-149, on behalf of the following class:

- *All persons residing in Canada who have taken and/or purchased the drug, ATORVASTATIN CALCIUM (sold under the brand name LIPITOR®) since March 5th 1997, and their successors, assigns, family members, and dependants, or any other group to be determined by the Court;*

Alternately (or as a subclass)

- *All persons residing in Quebec who have taken and/or purchased the drug, ATORVASTATIN CALCIUM (sold under the brand name LIPITOR®) since March 5th 1997, and their successors, assigns, family members, and dependants, or any other group to be determined by the Court;*

2. On September 13, 2019, the Plaintiff filed an Application for permission to discontinue the proposed class action (the “Application to Discontinue”), thereby putting an end to the proposed class action.

3. On October 29, 2019, the Plaintiff presented the Application to Discontinue and the Court suspended it to permit proposed class members to assert their rights.

4. If you wish to object to the proposed discontinuance, you must send a written submission to Class Counsel at the address listed below by February 13, 2020. In the written submission, you must include: (a) your full name, address, telephone number, and email address (if any); and (b) all of the reasons for your objection.

Consumer Law Group Inc.
1030 Berri St., Suite 102
Montreal, Quebec H2L 4C3
lipitor@clg.org

5. The judge will decide if there is a need for a hearing in Court or whether judgment can simply be rendered on the Application to Discontinue without a hearing. If the judge decides that a hearing in Court is necessary, any person that filed a written objection will be informed of the date, time, and place of such hearing and will have an opportunity to be heard by the judge.

BE AWARE that if the Court allows the discontinuance, the proposed class action is terminated. Limitation periods (i.e. prescription) will no longer be suspended. Therefore,

proposed class members will no longer be represented by the proposed class action and will be required to pursue their own action, should they so desire.

In this case, the period during which an action is allowed to be commenced had possibly begun to run from the date you learned of a problem related to Lipitor, until March 24, 2014, and the remaining period for class members to pursue their own action is therefore reduced accordingly.